-
Carcinoma
Derived from epithelial cells, those cells that line the type of our skin and organs.
-
Sarcoma
Derived from muscle, bone, cartilage, fat or connective tissues
-
Leukemia
Derived from white blood cells or their precursors
-
Lymphoma
A cancer of bone marrow derived cells that affects the lymphatic system
-
Myelomas
A cancer involving the white blood cells responsible for the production of antibiodies (B lymphocytes or B-cells)
-
Aromatic amines
bladder cancer
-
-
Asbestos
lung, mesothelioma
-
-
Vinyl chloride
liver angiosarcoma
-
EBV
Non-Hodgkin's lymphoma and nasopharyngeal cancer
-
HIV
Kaposi's sarcoma and lymphoma
-
HTLV1
Cutaneous T-lymphoma
-
-
Initiation
Exposure --> damage --> growth alterations and mutations
-
Promotion
Reversible changes favors growth of mutated cells
-
Transformation
Cells become cancerous
-
Progression
Additional genetic changes increase cancer proliferation
-
Oncogenes
- Defective genes involved in triggering cancer cell growth
- HER-2
-
Tumor-suppressor genes
- Normal genes responsible for control of cell division.
- p53
-
HER-2
- Encodes for the human epidermal growth factor receptor type 2
- It is involved in cellular responses to growth factors.
-
p53
Encodes for transcirption factor that regulates cell division, by triggering cell death (apoptosis) upon cellular injury.
-
Stages 0 and I
small localized cancer that are curable
-
Stages II and III
Locally advanced and/or involvement of local lymph nodes
-
Stage IV
Inoperable or metastatic cancer.
-
GX
grade cannot be assessed
-
-
G2
moderately differentiated
-
-
G4
undifferentiated (most aggressive and fast growing)
-
Neoadjuvant therapy
aims to shrink tumor and increase efficacy of primary therapy (reduce tumor cell burden)
-
Primary treatment
- surgery
- radiation
- chemotherapy
- biologic therapy
-
surgery
resection of solid localized tumors
-
Radiation
for curing localized tumors
-
Chemotherapy
systemic TTT against primary tumor and metastasis
-
Biologic therapy
Systemic TTT acts by stimulating host immune system
-
Adjuvant therapy
to eliminate all residual disease
-
curative
aims to at least reduce tumor burden below 10^3 cells
-
Palliative
- when complete eradication is unlikely
- aims to control symptoms, prolong survival time and increase QOL
-
Cell life: G1
- Postmitotic phase
- manufacture of enzymes for DNA synthesis
-
Cell life: G0
- Resting cells (not preparing division)
- serve as reserve for repopulation of tissue
- Generally not susceptible to chemo, esp. in slow growing tumors.
-
Cell life: S phase
DNA synthesis and replication
-
Cell life: G2
- premitotic phase
- making specialized proteins and RNA
-
Cell life: M
- mitosis
- actual cell division
-
DLT
toxicity to normal tissue that limits further dose escalation
-
MTD
Dose just below the DLT
-
Nadir
period of lowest blood cell counts, after chemotherapy TTT
|
|